Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Beijing, Xicheng District, China Clinical Trials

A listing of Beijing, Xicheng District, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (985) clinical trials

Registration Study of Takayasu's Arteritis in China

Objective: The study aims to investigate the demographic, clinical and prognostic features and to draw the diagnostic and therapeutic algorithm of Takayasu arteritis in China. Study Type: A national, multicenter, observational, ambispective cohort study. Study Design: The cardinal contents of this registry study are as follows: Select representative clinical centers ...

Phase N/A

0.0 miles

Learn More »

China Cognition and Aging Study

This study involved participants including amnestic mild cognitive impairment (aMCI), sporadic Alzheimer's disease (SAD), familial Alzheimer's disease (FAD), Vascular cognitive impairment (VCI), and APOE gene cohort (cognitive normal subjects). Research contents are as follow Neuropsychological characteristics of Chinese aMCI, SAD, VCI: analyze the cognitive function, daily living ability and mental ...

Phase N/A

0.0 miles

Learn More »

Study of Sulfatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

This study adopt Simon's two-stage designs method based on the primary endpoint of 16-week PFS rates. In the first stage, 16 patients will be recruited. If there are 3 or fewer patients without progression or death out of these 16 patients at week 16, the study will be stopped. Otherwise, ...

Phase

0.49 miles

Learn More »

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD. It consists of core study (12 weeks) and extension study (40 weeks). In the core study, patients will receive their assigned dose in a 50-L solution ...

Phase

0.49 miles

Learn More »

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel Carboplatin and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary ...

Phase

0.49 miles

Learn More »

BIOTRONIK Orsiro Pre-Marketing Registration

Clinical or call follow up visits will take place at 1, 6, 12, 24, 36, 48 and 60 months post procedure. At 9 months (+ 30 days) all subjects will undergo a standard quantitative coronary angiography (QCA) follow up to assess the in-stent LLL as the main efficacious evaluation. Use ...

Phase

0.49 miles

Learn More »

Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)

Study Purpose The safety and efficacy of paclitaxel controlled release balloon catheter VasoguardTM in treatment of small vessel lesion. Study Group Experimental group: paclitaxel controlled release balloon catheter (VasoguardTM) Control group: common balloon catheter (Maverick2)

Phase

0.49 miles

Learn More »

Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter

Study purpose The safety and efficacy of paclitaxel controlled release balloon catheter Vasoguard TM in treatment of in-stent restenosis. Study group Experimental group: paclitaxel controlled release balloon catheter Vasoguard TM Control group: paclitaxel release coronary balloon catheter SeQuent Please

Phase

0.49 miles

Learn More »

Phase III Study of Sulfatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

273 patients will be randomly assigned (in 2:1 ratio) to the Sulfatinib or Placebo treatment group based on interactive web response systemIWRS).The patients will receive continuous oral treatment, every 28-day treatment cycle until progression of disease occurs, intolerable toxicity or other protocol specified end-o-treatment criteria is met. The tumor should ...

Phase

0.49 miles

Learn More »

Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

195 patients will be randomly assigned (in 2:1 ratio) to the Sulfatinib or Placebo treatment group based on interactive web response systemIWRS).The patients will receive continuous oral treatment, every 28-day treatment cycle until progression of disease occurs, intolerable toxicity or other protocol specified end-o-treatment criteria is met. The tumor should ...

Phase

0.49 miles

Learn More »